{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:26:04Z","timestamp":1783416364495,"version":"3.54.6"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["31600269"],"award-info":[{"award-number":["31600269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Innovation Project of Chengdu Medical College","award":["YCX2024-01-99"],"award-info":[{"award-number":["YCX2024-01-99"]}]},{"name":"Collaborative Fund of Chengdu Medical College \u00e2\u20ac\u201c People\u00e2\u20ac\u2122s Hospital of Xindu District in Chengdu","award":["2022LHXD-01,23LHNBZYB18,24LHFYSZ1-32"],"award-info":[{"award-number":["2022LHXD-01,23LHNBZYB18,24LHFYSZ1-32"]}]},{"name":"Science and Technology Program of Sichuan Province","award":["2025ZNSFSC0551"],"award-info":[{"award-number":["2025ZNSFSC0551"]}]},{"name":"Scientific Research Project of Chengdu Medical College","award":["CYZZD24-10"],"award-info":[{"award-number":["CYZZD24-10"]}]},{"name":"Special Project of Liyan Workshop Medical Aesthetics Research Center","award":["23YM04"],"award-info":[{"award-number":["23YM04"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      We have purified Momordica anti-HIV protein of 30\u2009kDa (MAP30), a type I ribosome-inactivating protein from\n                      <jats:italic toggle=\"yes\">Momordica charantia<\/jats:italic>\n                      L. with approximately 30\u2009kDa, which inhibited protein synthesis through N-glycosylase activity and exhibited antiviral, antibacterial, antitumor and other biological activities. It is speculated that MAP30 may be a potential natural active agent for prevention and treatment of liver cancer. However, its effect on liver cancer and underlying mechanism are still unclear now. Therefore, the purpose of this manuscript was to explore the molecular mechanism of MAP30 on liver cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The cell counting kit-8 assay was used to detect the proliferation of SK-Hep-1 cells. The apoptosis, cell cycle, reactive oxygen species level and mitochondrial membrane potential of SK-Hep-1 cells were detected by flow cytometry. Protein levels were determined by Western blot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>It was confirmed that MAP30 can significantly inhibit the proliferation of SK-Hep-1 cells, arrest the cell cycle in G1 phase and induce apoptosis. Further studies on apoptosis-related proteins showed that the expression of caspase-3, caspase-9, poly (ADP-ribose) polymerase and B-cell lymphoma 2 proteins decreased synchronously in a time- and dose-dependent manner. In addition, MAP30-induced apoptosis of SK-Hep-1 cells was found to be closely related to the mitochondrial pathway through the increase of reactive oxygen species and the decrease of mitochondrial membrane potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The manuscript indicated that MAP30 may be a potential antitumor drug which provided an experimental basis for further exploration of the mechanism of MAP30 prevention and treatment of liver cancer, and was expected to be applied in medicine and biotechnology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048838","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:00:09Z","timestamp":1779469209000},"page":"e48838","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["MAP30, a type \u2160 ribosome-inactivating protein, inhibits hepatocellular carcinoma by inducing apoptosis through mitochondria"],"prefix":"10.1097","volume":"105","author":[{"given":"Di","family":"Yang","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Peng","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine, Chengdu Medical College, Clinical IVD Joint Research Center of Chengdu Medical College-Maccura Biotechnology, Sichuan Provincial Engineering Laboratory for Prevention and Control Technology of Veterinary Drug Residue in Animal-Origin Food, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Jia","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine, Chengdu Medical College, Clinical IVD Joint Research Center of Chengdu Medical College-Maccura Biotechnology, Sichuan Provincial Engineering Laboratory for Prevention and Control Technology of Veterinary Drug Residue in Animal-Origin Food, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sichuan Provincial People\u2019s Hospital, Jinniu Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houke","family":"Li","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine, Chengdu Medical College, Clinical IVD Joint Research Center of Chengdu Medical College-Maccura Biotechnology, Sichuan Provincial Engineering Laboratory for Prevention and Control Technology of Veterinary Drug Residue in Animal-Origin Food, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5196-2336","authenticated-orcid":false,"given":"Zongxing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Chengdu Xindu District People\u2019s Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1257-1479","authenticated-orcid":false,"given":"Yao","family":"Meng","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine, Chengdu Medical College, Clinical IVD Joint Research Center of Chengdu Medical College-Maccura Biotechnology, Sichuan Provincial Engineering Laboratory for Prevention and Control Technology of Veterinary Drug Residue in Animal-Origin Food, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020.","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"R2-20260707","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040.","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","article-title":"Diagnosis and treatment of hepatocellular carcinoma.","volume":"134","author":"El-Serag","year":"2008","journal-title":"Gastroenterology"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/187153008784534330","article-title":"Traditional chinese medicine in treatment of metabolic syndrome.","volume":"8","author":"Yin","year":"2008","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.3390\/ijerph16183251","article-title":"The role of momordica charantia in resisting obesity.","volume":"16","author":"Fan","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0304-4157(93)90002-6","article-title":"Ribosome-inactivating proteins from plants.","volume":"1154","author":"Barbieri","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.toxicon.2004.05.004","article-title":"Ribosome-inactivating proteins.","volume":"44","author":"Stirpe","year":"2004","journal-title":"Toxicon"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbapap.2004.06.004","article-title":"Cytotoxic ribosome-inactivating lectins from plants.","volume":"1701","author":"Hartley","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.febslet.2005.01.038","article-title":"Ribosome inactivating proteins and apoptosis.","volume":"579","author":"Narayanan","year":"2005","journal-title":"FEBS Lett"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0092-8674(00)81529-9","article-title":"Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions.","volume":"99","author":"Wang","year":"1999","journal-title":"Cell"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1007\/s00253-015-6941-2","article-title":"Biological activities of ribosome-inactivating proteins and their possible applications as antimicrobial, anticancer, and anti-pest agents and in neuroscience research.","volume":"99","author":"Akkouh","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0015-0282(99)00302-7","article-title":"The antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may be useful in preventing the sexual transmission of human immunodeficiency virus type 1.","volume":"72","author":"Schreiber","year":"1999","journal-title":"Fertil Steril"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsb.2008.06.011","article-title":"Atomic resolution structure of cucurmosin, a novel type 1 ribosome-inactivating protein from the sarcocarp of Cucurbita moschata.","volume":"164","author":"Hou","year":"2008","journal-title":"J Struct Biol"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"105157","DOI":"10.1016\/j.phrs.2020.105157","article-title":"MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.","volume":"161","author":"Chan","year":"2020","journal-title":"Pharmacol Res"},{"key":"R16-20260707","first-page":"5833","article-title":"MAP30 promotes apoptosis of U251 and U87 cells by suppressing the LGR5 and Wnt\/beta-catenin signaling pathway, and enhancing Smac expression.","volume":"15","author":"Jiang","year":"2018","journal-title":"Oncol Lett"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0378-1119(95)00186-A","article-title":"Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon.","volume":"161","author":"Lee-Huang","year":"1995","journal-title":"Gene"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1574892818666221103114649","article-title":"Ribosome-inactivating protein MAP30 isolated from Momordica charantia L. induces apoptosis in hepatocellular carcinoma cells.","volume":"19","author":"Zhou","year":"2024","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"R19-20260707","first-page":"3133","article-title":"Preparation of an antitumor and antivirus agent: chemical modification of alpha-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.","volume":"7","author":"Meng","year":"2012","journal-title":"Int J Nanomedicine"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"C198","DOI":"10.1152\/ajpcell.00256.2018","article-title":"ROS-induced autophagy regulates porcine trophectoderm cell apoptosis, proliferation, and differentiation.","volume":"316","author":"Luo","year":"2019","journal-title":"Am J Physiol Cell Physiol"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1009616228304","article-title":"Role of reactive oxygen species (ROS) in apoptosis induction.","volume":"5","author":"Simon","year":"2000","journal-title":"Apoptosis"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.pharmthera.2021.107843","article-title":"Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms.","volume":"225","author":"Huang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.fct.2018.05.024","article-title":"Bitter gourd (Momordica charantia) as a rich source of bioactive components to combat cancer naturally: are we on the right track to fully unlock its potential as inhibitor of deregulated signaling pathways.","volume":"119","author":"Farooqi","year":"2018","journal-title":"Food Chem Toxicol"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3390\/ijms18122555","article-title":"Recent advances in momordica charantia: functional components and biological activities.","volume":"18","author":"Jia","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2016.07.002","article-title":"Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.","volume":"40-41","author":"Raina","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"R26-20260707","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/156652411795976583","article-title":"Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties.","volume":"11","author":"Fang","year":"2011","journal-title":"Curr Mol Med"},{"key":"R27-20260707","first-page":"81","article-title":"Bitter melon: a panacea for inflammation and cancer.","volume":"14","author":"Dandawate","year":"2016","journal-title":"Chin J Nat Med"},{"key":"R28-20260707","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2012.05.005","article-title":"The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo.","volume":"324","author":"Fang","year":"2012","journal-title":"Cancer Lett"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10495-011-0684-z","article-title":"RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways.","volume":"17","author":"Fang","year":"2012","journal-title":"Apoptosis"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/1940-6207.CAPR-11-0203","article-title":"Momordica Charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo.","volume":"5","author":"Fang","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"R31-20260707","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djq315","article-title":"Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.","volume":"102","author":"Seoane","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R32-20260707","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10495-011-0597-x","article-title":"Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment.","volume":"16","author":"Zhang","year":"2011","journal-title":"Apoptosis"},{"key":"R33-20260707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.12.027","article-title":"Lariciresinol induces apoptosis in HepG2 cells via mitochondrial-mediated apoptosis pathway.","volume":"821","author":"Ma","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"R34-20260707","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-94-007-2869-1_7","article-title":"The mitochondrial pathways of apoptosis.","volume":"942","author":"Estaquier","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"R35-20260707","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1015921513720","article-title":"Control of mitochondrial membrane potential and ROS formation by reversible phosphorylation of cytochrome c oxidase.","volume":"234-235","author":"Lee","year":"2002","journal-title":"Mol Cell Biochem"},{"key":"R36-20260707","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41418-023-01187-0","article-title":"Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions.","volume":"30","author":"Bernardi","year":"2023","journal-title":"Cell Death Differ"},{"key":"R37-20260707","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","article-title":"BCL-2 family: regulators of cell death.","volume":"16","author":"Chao","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"R38-20260707","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tibs.2013.12.006","article-title":"Many players in BCL-2 family affairs.","volume":"39","author":"Moldoveanu","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"R39-20260707","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bjc.2015.85","article-title":"Mitochondrial apoptosis: killing cancer using the enemy within.","volume":"112","author":"Lopez","year":"2015","journal-title":"Br J Cancer"},{"key":"R40-20260707","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1073\/pnas.96.10.5752","article-title":"Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia.","volume":"96","author":"Krajewski","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"R41-20260707","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2007.01.003","article-title":"Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.","volume":"10","author":"Maddika","year":"2007","journal-title":"Drug Resist Updat"},{"key":"R42-20260707","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tcb.2015.12.002","article-title":"TNF and ROS crosstalk in inflammation.","volume":"26","author":"Blaser","year":"2016","journal-title":"Trends Cell Biol"},{"key":"R43-20260707","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2174\/156652409789839071","article-title":"Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy.","volume":"9","author":"Puri","year":"2009","journal-title":"Curr Mol Med"},{"key":"R44-20260707","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/abbs\/gmp068","article-title":"Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol.","volume":"41","author":"Li","year":"2009","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"R45-20260707","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/aps.2016.53","article-title":"Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach.","volume":"37","author":"Qi","year":"2016","journal-title":"Acta Pharmacol Sin"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:00:43Z","timestamp":1783414843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":45,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048838","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2024-10-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}